Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

PREDNISOLONE Tablet (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Prednisolone 10mg Tablets.

Qualitative and quantitative composition

Each tablet contains 10 mg prednisolone. For the full list of excipients, see section 6.1.

Pharmaceutical form

Tablets. 10mg tablet: Red, 7mm, round, flat, tablet, with a score line on one side, imprinted with A630 on one side and 10 on the other.

Therapeutic indications

Allergy and anaphylaxis: bronchial asthma, drug hypersensitivity reactions, serum sickness, angioneurotic oedema, anaphylaxis, incapacitating allergies unresponsive to conventional treatment. Arteritis/collagenosis: ...

Posology and method of administration

Posology Adults and the elderly The lowest effective dose should be used for the minimum period. Children Prednisolone should only be used when specifically indicated, at the lowest dose possible and for ...

Contraindications

Prednisolone is contraindicated in: Hypersensitivity to the active substance or any of the excipients listed in section 6.1. Systemic infections unless specific anti-infective therapy is employed. Ocular ...

Special warnings and precautions for use

Patients and/or carers should be warned that potentially severe psychiatric adverse reactions may occur with systemic steroids (see Section 4.8). Symptoms typically emerge within a few days or weeks of ...

Interaction with other medicinal products and other forms of interaction

Vaccines: Live vaccines should not be given to individuals with impaired immune responsiveness. The antibody response to other vaccines may be diminished. Antacids: The absorption of prednisolone may be ...

Fertility, pregnancy and lactation

Pregnancy The ability of corticosteroids to cross the placenta varies between individual drugs, however 88% of prednisolone is inactivated as it crosses the placenta. Administration of corticosteroids ...

Effects on ability to drive and use machines

The effect of Prednisolone on the ability to drive or use machinery has not been evaluated. There is no evidence to suggest that prednisolone may affect these abilities.

Undesirable effects

A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, ...

Overdose

Reports of acute toxicity and/or death following overdosage of glucocorticoids are rare. No specific antidote is available; treatment is supportive and symptomatic. Serum electrolytes should be monitored. ...

Pharmacodynamic properties

Pharmacotherapeutic group: glucocorticoid steroid ATC code: H02AB06 Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement ...

Pharmacokinetic properties

Prednisolone is rapidly and apparently almost completely absorbed after oral administration; it reaches peak plasma concentrations after 1-3 hours. There is however wide inter-subject variation suggesting ...

Preclinical safety data

There are no non-clinical data of relevance to the prescriber that are not already covered in other sections of the SmPC.

List of excipients

Lactose monohydrate Pregelatinised starch Sodium starch glycolate, type A Iron oxide yellow (E172) Iron oxide red (E172) Glycerol dibehenate Magnesium stearate

Incompatibilities

None known.

Shelf life

24 months.

Special precautions for storage

Keep the blister packs in the outer carton in order to protect from light.

Nature and contents of container

Blisters of AL/PVC containing packs of 28 tablets. Not all pack sizes may be marketed.

Special precautions for disposal and other handling

Not available.

Marketing authorization holder

Actavis UK Limited (Trading style: Actavis), Whiddon Valley, Barnstaple, N. Devon, EX32 8NS

Marketing authorization number(s)

PL 00142/0843

Date of first authorization / renewal of the authorization

01/04/2016

Date of revision of the text

14/02/2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: